DOI: https://doi.org/10.18370/2309-4117.2018.44.24-28

Reproductive, clinical and biological markers of perimenopause

О. О. Єфіменко, І. М. Ретунськ, О. С. Зеленько

Abstract


The problems of aging women both in the world and in our country are becoming increasingly relevant. The sharp increase in the incidence among women of the age category, which coincides with the age of menopause, is a serious argument for considering this period and the associated changes as one of the priorities of modern medicine. Already today, despite the general tendency to aging of the population, a third of the life of the majority of women falls on the post-menopausal period, which acquires a special social and even state significance. However, these changes begin at a younger age, which requires close attention of specialists, because it is at this stage that the development of long-term programs to preserve both the reproductive and the general health of the female population is important.

The article considers modern views on the problem of ovarian function diminishing in perimenopause and the problem of aging in general. Reproductive and biological age markers and hormonal disorders causing clinical manifestations of perimenopause are given. Attention is paid to the definition of psychological age, its influence on the psychological status of a woman whose passport age is over 40 years old, which coincides with the peak of her professional and social activities. Analyzed modern views on improving the quality of life of women who are in the perimenopausal period.

Currently, there are many methods for timely assessment of disorders in systems and organs that can provoke the occurrence of age-related diseases. Therefore, the task of modern medicine is to prevent early aging and introduce preventive methods that improve the quality of life and increase its duration. As the authors of the article note, the assessment of biological and reproductive age is important for the prevention of diseases that can be avoided by following simple guidelines for optimizing lifestyle.


Keywords


perimenopause; reproductive age; biological age; follicular reserve; early perimenopausal disorders; telomeres; psychological age; somatomedin; IGF 1; melatonin

References


Schneider, H.P. “The view of the international Menopause Society on the Women’s Health Initiative.” Climacteric 5 (2002): 211–6.

Rosemeier, H.P., Schultz-Zehden, B. “Assessing well-being in menopausal women.” In: The Management of the Menopause. Ed. By J. W.W. Studd. New York. Parphenon Publishing Group (2000): 11–9.

Medicine of menopause. Yaroslavl. Publishing House Litera Ltd (2006): 846 p.

Birge, S.J. “Estrogen and the brain: implication for menopause managmant.” In: Menopause. The State of the Art – in research and management. Ed. by P.G. Schneider. The Parthenon Publishing Group (2002): 191–5.

Mishieva, N.G. Infertility in women of late reproductive age: principles of diagnosis and treatment, depending on the ovarian reserve. Thesis abstract for MD degree. Moscow (2008).

Hazout, A., Bouchard, P., et al. “Serum anti-mullerian hormone/mullerian-inhibitimg substance appears to be a more discriminatory market of assisted reproductive technology outcome than follicle-stimulation hormon, ingibin B, or estradiol.” Fertil Steril 82.5 (2004): 1323–9.

Rooij, I.A., Tonkelaar, I., et al. “Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition.” Menopause 11.6 P 1 (2004): 585–6.

Gruber, C., Tschuggurl, W. “Production and action of estrogen.” N Engl J Med 346.5 (2002): 340–6.

Furucawa, Т., et al. “Assesment of biological age.” J Gerontol 30.4 (1975): 422.

Chok, N.W. “Indices of functional age.” In: Aging: A challenge to science and society. Oxford University Press (1981): 270–86.

Gomes, N., Ryder, O., Houck, M., et al. “Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination.” Aging Cell 10 (2011): 761–8.

Zvereva, M., Rubtsova, N. “Nobel Prize in Physiology and Medicine, 2009. Cell Time Counter.” Science and Life 1 (2010): 2–5.

Zuev, V.A., Trifonov, N.I., Linkova, N.S., Kvetnaya, T.V. “Melatonin as a molecular marker of age pathology.” Successes of gerontology 1 (2017): 63–70.

Jan, J.E., Espezel, H., Appleton, R.E. “The treatment of sleep disorders with melatonin.” Dev Med Child Neurol 36 (1994): 97–107.

Spengos, K., Tsivgoulis, G., Manios, E., et al. “Common carotid artery intima-media thickness is an independent predictor of long-term recurrence in stroke patients.” Stroke 34 (2003): 1623–7.

Folsom, A.R., Eckfeldt, J.H., Weitzman, S., et al. “For the Atherosclerosis Risk in communities (ARIC) Study Investigators Relation of carotid artery wall thikness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity.” Stroke 25 (1994): 66–73.

Kidd, P.M. “Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.” Altern Med Rev 13 (2008): 85–115.

Malinow, M.R. “Plasma concentrations of total homocysteine predict mortality risk.” Am J Clin Nutr 74 (2001): 3.

Clemmons, D.R. “Modifying IGF-I activity: an approach to treat endocrine disorders, atherosclerosis and cancer.” Nat Rev Drug Discov 6.10 (2007): 821–33.

Tritos, N.A., Greenspan, S.L., King, D., et al. “Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis.” J Clin Endocrinol Metab 96.5 (2011): 1516–23.

Abraham, A., Cohen, A., Shane, E. “Premenopausal bone health: osteoporosis in premenopausal women.” Clin Obstet Gynecol 56.4 (2013): 722–9.


GOST Style Citations


1.           Schneider, H.P. “The view of the international Menopause Society on the Women’s Health Initiative.” Climacteric 5 (2002): 211–6.

2.           Rosemeier, H.P., Schultz-Zehden, B. “Assessing well-being in menopausal women.” In: The Management of the Menopause. Ed. By J. W.W. Studd. New York. Parphenon Publishing Group (2000): 11–9.

3.           Сметник, В.П.  Медицина климактерия . – Ярославль: ООО «Издательство Литера», 2006. – 846 с. Smetnik, V.P.

4.           Birge, S.J. “Estrogen and the brain: implication for menopause managmant.” In: Menopause. The State of the Art – in research and management. Ed. by P.G. Schneider. The Parthenon Publishing Group (2002): 191–5.

5.           Мишиева, Н.Г. Бесплодие у женщин позднего репродуктивного возраста: принципы диагностики и лечения в зависимости от овариального резерва : автореф. дисс. … д. мед. н. /

Н.Г. Мишиева. – М., 2008.

6.           Hazout, A., Bouchard, P., et al. “Serum anti-mullerian hormone/mullerian-inhibitimg substance appears to be a more discriminatory market of assisted reproductive technology outcome than follicle-stimulation hormon, ingibin B, or estradiol.” Fertil Steril 82.5 (2004): 1323–9.

7.           Rooij, I.A., Tonkelaar, I., et al. “Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition.” Menopause 11.6 P 1 (2004): 585–6.

8.           Gruber, C., Tschuggurl, W. “Production and action of estrogen.” N Engl J Med 346.5 (2002): 340–6.

9.           Furucawa, Т., et al. “Assesment of biological age.” J Gerontol 30.4 (1975): 422.

10.         Chok, N.W. “Indices of functional age.” In: Aging: A challenge to science and society. Oxford University Press (1981): 270–86.

11.         Gomes, N., Ryder, O., Houck, M., et al. “Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination.” Aging Cell 10 (2011): 761–8.

12.         Зверева, М. Нобелевская премия по физиологии и медицине 2009 года. Счетчик клеточного времени / М. Зверева, Н. Рубцова // Наука и жизнь. – 2010. – № 1. – С. 2–5.

13.         Зуев, В.А. Мелатонин как молекулярный маркер возрастной патологии / В.А. Зуев, Н.И. Трифонов, Н.С. Линькова, Т.В. Кветная // Успехи геронтологии. – 2017. – №1. – С. 63–70.

14.         Jan, J.E., Espezel, H., Appleton, R.E. “The treatment of sleep disorders with melatonin.” Dev Med Child Neurol 36 (1994): 97–107.

15.         Spengos, K., Tsivgoulis, G., Manios, E., et al. “Common carotid artery intima-media thickness is an independent predictor of long-term recurrence in stroke patients.” Stroke 34 (2003): 1623–7.

16.         Folsom, A.R., Eckfeldt, J.H., Weitzman, S., et al. “For the Atherosclerosis Risk in communities (ARIC) Study Investigators Relation of carotid artery wall thikness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity.” Stroke 25 (1994): 66–73.

17.         Kidd, P.M. “Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.” Altern Med Rev 13 (2008): 85–115.

18.         Malinow, M.R. “Plasma concentrations of total homocysteine predict mortality risk.” Am J Clin Nutr 74 (2001): 3.

19.         Clemmons, D.R. “Modifying IGF-I activity: an approach to treat endocrine disorders, atherosclerosis and cancer.” Nat Rev Drug Discov 6.10 (2007): 821–33.

20.         Tritos, N.A., Greenspan, S.L., King, D., et al. “Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis.” J Clin Endocrinol Metab 96.5 (2011): 1516–23.

21.         Abraham, A., Cohen, A., Shane, E. “Premenopausal bone health: osteoporosis in premenopausal women.” Clin Obstet Gynecol 56.4 (2013): 722–9.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)